Aim: To analyze the relationship between pretreatment clinical or histological features and the levels of soluble platelet-endothelial cell adhesion molecule-1 (sPECAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1), to determine their serum concentration in responders and nonresponders, to evaluate the behavior under antiviral therapy, to explain their relationship in response to therapy and to assess the association between these two molecules in chronic hepatitis C (CHC).
Methods: The study analyzed 65 CHC patients, including 50 patients (Group 1) with marked fibrosis treated with peginterferon plus ribavirin, 15 patients without fibrosis (Group 2) and 13 healthy volunteers (the control group, Group 3). sPECAM-1 and sVCAM-1 levels were assessed by an immunoenzymatic method (ELISA) before and after therapy.
Results: sVCAM-1 and sPECAM-1 serum concentrations increased significantly in CHC patients (p<0.001). sPECAM-1 levels corresponded to inflammatory grade (p = 0.03) and fibrosis stage (p = 0.01). sVCAM-1 increased only in advanced fibrosis. After therapy, sPECAM-1 levels decreased significantly (p<0.001) with no difference between responders and nonresponders. sPECAM-1 correlated positively with inflammatory activity (p = 0.02), fibrosis stage (p<0.001), sVCAM-1 (r = 0.56, p<0.001) and alanine aminotransferase activity (r = 0.30, p = 0.05). Receiver operating characteristic curve analysis showed a good discriminant power of serum sPECAM-1 concentrations for detection of liver fibrosis — stage 0 versus stage 1—3, AUC 0.81; cut-off 221.0 ng/ml and a fair discriminant power for distinguishing bridging fibrosis, AUC 0.78; cut-off 237.1 ng/ml.
Conclusions: Hepatitis C virus (HCV) infection results in upregulation of sPECAM-1 and sVCAM-1. sPECAM-1 levels are related to necroinflammatory activity and may also identify patients with advanced fibrosis. The sPECAM-1 value was decreased by therapy but its measurement cannot predict therapy outcome and confirm HCV persistence. sPECAM-1 may influence VCAM-1 expression.
Ballardini, G., Groff, P., Pontisso, P., Giostra, F., Francesconi, R., Lenzi, M. et al. (1995) Hepatitis C (HCV) virus genotype, tissue HCV antigens, hepatocellular expression of HLA-A, B, C and intercellular adhesion 1 molecules. Clues to pathogenesis of hepatocellular damage and response to interferon treatment in patients with chronic hepatitis C, J Clin Invest95: 2067-2075.
2.
Bhunchet, E. and Fujieda, K. (1995) Capillarization and venularization of hepatic sinusoids in porcine serum-induced rat liver fibrosis: a mechanism to maintain liver flow, Hepatology18: 1450-1458.
3.
Brillanti, S., Foli, M., Gaiani, S., Masci, C., Miglioli, M. and Barbara, L. (1993) Persistent hepatitis C viraemia without liver disease , Lancet341: 464-465.
4.
Bruno, C.M., Sciacca, C., Cilio, D., Bertino, G., Marchese, A.E., Politi, G. et al. (2005) Circulating adhesion molecules in patients with virus-related chronic diseases of the liver, World J Gastroenterol11: 4566-4569.
5.
Cerny, A., McHutchison, J.G., Pasquinelli, C., Brown, M.E., Brothers, M.A., Grabscheid, B. et al. (1995) Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif, J Clin Invest95: 521-530.
6.
Dejica, D., Grigorescu, M., Dejica, V., Radu, C. and Neculoiu, D. (2002) Serum levels of soluble intercellular-1 and vascular cell-1 adhesion molecules in chronic hepatitis C and the influence of interferon-alpha + ribavirin therapy, Rom J Gastroenterol11: 277-283.
7.
DeLeve, L.D., Wang, X., Hu, L., McCuskey, M.K. and McCuskey, R.S. (2004) Rat liver sinusoidal endothelial cell phenotype is maintained by paracrine and autocrine regulation, Am J Physiol Gastrointest Liver Physiol287: G757-763.
Engelhardt, B. and Wolburg, H. (2004) Trans-endothelial migration of leukocytes: through the front door or around the side of the house? Eur J Immunol34: 2955-2963.
10.
Friedmann, S.L. (2003) Liver fibrosis- from banch to bedside, J Hepatol30: 38-53.
11.
Fukuda, Y., Nakano, I., Katano, Y., Marui, A. and Hayakawa, T. (1998) Serum levels of soluble intercellular adhesion molecule-1 and soluble vascular cell adhesion molecule-1 in asymptomatic carriers of hepatitis C virus, J Int Med Res26: 313-318.
12.
Gabriel, A. and Ziółkowski, A. (1997) New terminology of chronic hepatitis, including a scoring scale, Med Sci Monit3: 113-118.
13.
Garcia-Monzon, C., Sanchez-Madrid, F., Garcia-Buey, L., Garcia-Sanchez, A. and Moreno-Otero, R. (1995) Vascular adhesion molecule expression in viral chronic hepatitis: evidence of neoangiogenesis in potral tracts, Gastroenterology108: 231-241.
14.
Gearing, A.J.H. and Newman, W. (1993) Circulating adhesion molecules in disease, Immunol Today14: 506-512.
15.
Goel, R., Boylan, B., Gruman, L., North, P.E. and Newman, D.K. (2007) The proinflammatory phenotype of PECAM-1-deficient mice results in atherogenic diet-induced steatohepatitis, Am J Physiol Gastrointest Liver Physiol293: G1205-1214.
16.
Gonzalez-Amaro, R., Diaz-Gonzalaz, F. and Sanchez-Madrid, F. (1998) Adhesion molecules in inflammatory diseases, Drugs56: 977-988.
17.
Graesser, D., Solowiej, A., Bruckner, M., Osterweil, E., Juedes, A., Davis, S. et al. (2002) Altered vascular permeability and early onset of experimental autoimmune encephalomyelitis in PECAM-1-deficient mice , J Clin Invest109: 383-392.
18.
Granot, E., Shouval, D. and Ashur, Y. (2001) Cell adhesion molecules and hyaluronic acid as markers of inflammation, fibrosis and response to antiviral therapy in chronic hepatitis C patients, Mediators Inflamm10: 253-258.
19.
Gressner, A.M. and Weiskirchen, R. (2006) Modern pathogenesis concepts of liver fibrosis suggest stellate cells and TGF-b as major players and therapeutic targets , J Cell Mol Med10: 76-99.
Kapllanski, G., Farnarier, C., Payan, M.J., Bongrand, P. and Durand, J.M. (1997) Increased levels of soluble adhesion molecules in the serum of patients with hepatitis C. Correlation with cytokine concentrations and liver inflammation and fibrosis, Dig Dis Sci42: 2277-2284.
22.
Katz, S.C., Pillarisetty, V.G., Bleier, J.I., Shah, A.B. and DeMatteo, R.P. (2004) Liver sinusoidal endothelial cells are insufficient to activate T cells, J Immunol173: 230-235.
23.
Lalor, P.F., Shields, P., Grant, A.J. and Adams, D.H. (2002) Recruitment of lymphocytes to the human liver, Immunol Cell Biol80: 52-64.
24.
Lang, T., Krams, S.M., Villanueva, J.C., Cox, K., So, S. and Martinez, O.M. (1995) Differential patterns of circulating intercellular adhesion molecule -1 (cICAM-1) and vascular cell adhesion molecule -1 (cVCAM-1) during liver allograft rejection, Transplantation59: 584-589.
25.
Ley, K. (1996) Molecular mechanisms of leukocyte recruitment in the inflammatory process, Cardiovasc Res32: 733-742.
26.
Lo Iacono, O., Garcia-Monzon, C., Almasio, P., García-Buey, L., Craxí, A. and Moreno-Otero, R. (1998) Soluble adhesion molecules correlate with liver inflammation and fibrosis in chronic hepatitis C treated with interferon -α, Aliment Pharmacol Ther12: 1091-1099.
27.
Marui, A., Fukuda, Y., Koyama, Y., Nakano, I., Urano, F., Hamada, M. et al. (1996) Serum levels of soluble intercellular adhesion molecule-1 and soluble vascular cell adhesion molecule-1 in liver disease, and their changes by treatment with interferon, J Int Med Res24: 258-265.
28.
Neubauer, K., Wilfling, T., Ritzel, A. and Ramadori, G. (2000) Platelet-endothelial cell adhesion molecule-1 gene expression in liver sinusoidal endothelial cells during liver injury and repair , J Hepatol32: 921-932.
29.
Newman, P.J. (1997) The biology of PECAM-1, J Clin Invest99: 3-8.
30.
Newman, P.J. and Newman, D.K. (2003) Signal transduction pathways mediated by PECAM-1. New roles for an old molecule in platelet and vascular biology, Arterioscler Thromb Vasc Biol23: 953-964.
31.
Petri, B. and Bixel, M.G. (2006) Molecular events during leukocyte diapedesis, FEBS J273: 4399-4407.
32.
Pober, J.S. and Cotran, R.S. (1990) The role of endothelial cells in inflammation, Transplantation50: 537-544.
33.
Prager, E. and Stockinger, H. (2000) CD31, J Biol Regul Homeost Agents14: 307-310.
34.
Rachwal, A.W. and Brigstock, D.R. (2003) Connective tisssue growth factor (CTGF/CCN2) in hepatic fibrosis, Hepatol Res26: 1-9.
35.
Radu, C., Dejica, D., Grigorescu, M., Zaharie, T. and Neculoiu, D. (2003) Correlation of sICAM-1 and sVCAM-1 level with biochemical, histological and viral findings in chronic hepatitis C after interferon-alpha + ribavirin therapy, Rom J Gastroenterol12: 91-95.
36.
RayChaudhury, A., Elkins, M., Kozien, D. and Nakada, M.T. (2001) Regulation of PECAM-1 in endothelial cells during cell growth and migration, Exp Biol Med226: 686-691.
37.
Scalia, R. and Lefer, A.M. (1998) In vivo regulation of PECAM-1 activity during acute endothelial dysfunction in the rat mesenteric microvasculature, J Leukoc Biol64: 163-169.
38.
Scheuer, P.J. (1995) The nomenclature of chronic hepatitis: time for a change, J Hepatol22: 112-114.
39.
Shah, V., Toruner, M., Haddad, F., Cadelina, G., Papapetropoulos, A., Choo, K. et al. (1999) Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat, Gastroenterology117: 1222-1228.
40.
Simpson, K.J., Harrison, D.J. and Hayes, P.C. (1994) Serum and tissue vascular adhesion molecules in hepatitis C infection, Gut35(Suppl. 5): S68.
41.
Steinhoff, G., Behrend, M., Schrader, B., Duijvestijn, A.M. and Wonigeit, K. (1993) Expression patterns of leukocyte adhesion ligand molecules on human liver endothelia. Lack of ELAM-1 and CD62 inducibility on sinusoidal endothelia and distinct distribution of VCAM-1, ICAM-1, ICAM-2, and LFA-3, Am J Pathol142: 481-488.
42.
Volpes, R., Van den Oord, J.J. and Desmet, V.J. (1992) Vascular adhesion molecules in acute and chronic liver inflammation, Hepatology15: 269-275.
43.
Xu, B., Broome, U., Uzunel, M., Nava, S., Ge, X., Kumagai-Braesch, M. et al. (2003) Capillarization of hepatic sinusoid by liver endothelial cell-reactive autoantibodies in patients with cirrhosis and chronic hepatitis, Am J Pathol163: 1275-1289.
44.
Ziółkowski, A., Wylezol, M., Kukla, M., Żwirska- İ.Korczala, K., Berdowska, A., Jędrzejowska-Szypulka, H. et al. (2005) Factors associated with steatosis and necroinflammatory activity in morbidly obese patients with non-alcoholic fatty liver disease, Pol J Environ Stud14(Suppl. 2): 417-420.
